Inactive Instrument

Silence Therapeutics plc London S.E.

Equities

GB0008433350

End-of-day quote London S.E. Other stock markets
- ^GBX	-

07-17	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
07-12	European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	MT

Silence Therapeutics : Key European patent granted

January 22, 2018 at 07:14 am

Key European patent granted

22 January 2018

Silence Therapeutics plc, AIM:SLN ('Silence' or 'the Company') a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that on 17 January 2018 the European Patent Office granted a further European patent EP 1857547B to Silence.

The allowed claims of European patent EP 1857547B will provide Silence with further protection for its innovative chemical modification technology in Europe. Silence seeks to protect the value of its portfolio and investment, where necessary using all the legal means at its disposal.

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:

'These newly granted claims add further value to our intellectual property portfolio, and strengthen our patent position in Europe.'

Enquiries:

Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer	Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel: +44 (0)20 7418 8900
Media Enquiries Optimum Strategic Communications Mary Clark/ Eva Haas/ Hollie Vile silence@optimumcomms.com	Tel: +44 (0)20 3714 1788

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. http://www.silence-therapeutics.com

Silence Therapeutics plc published this content on 22 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 January 2018 07:14:07 UTC.

Original documenthttps://polaris.brighterir.com/public/silence_therapeutics/news/rns/story/rdvqpmr

Public permalinkhttp://www.publicnow.com/view/7C3A64D439230B2A67E348BAF55D74259F3B9273

Latest news about Silence Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	07-17	MT
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	07-12	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	07-08	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	07-02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	06-28	MT
Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating	06-28	MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating	06-28	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	06-27	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-27	MT
Silence Therapeutics Says Divesiran Shows Sustained Hematocrit Reduction in Blood Cancer Study	06-27	MT
Transcript : Silence Therapeutics plc - Special Call	06-27
Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	06-27	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	06-26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	06-21	MT
Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)	06-20	CI
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	06-17	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	06-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	05-30	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	05-28	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	05-22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	05-21	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	05-20	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
Silence Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI

Chart Silence Therapeutics plc

Duration

Period

More charts

Company Profile

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is focused on discovering and developing molecules incorporating short-interfering ribonucleic acid (siRNA) to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body's natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target disease-associated genes in the liver. Its wholly owned product candidates include SLN360, for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein (a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).

Sector

Calendar

11/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company